Theratechnologies reports Q2 2024 sales of $22.02 million, a 25.5% YoY increase, driven by strong demand for EGRIFTA SV. Net income reached $1 million with an adjusted EBITDA of $5.5 million. The company expects FY 2024 revenue of $87-$90 million and adjusted EBITDA of $13-$15 million.
Read more